LIDE has established 1700+ high quality PDX models in more than 40 cancer types – one of the largest coverage of any PDX bio bank in the world.
Cancer | No. | Cancer | No. | Cancer | No. |
Pancreatic | 299 | Sarcoma | 26 | AML | 13 |
Gastric | 193 | Cervical | 16 | ALL | 9 |
Ovarian | 186 | Endometrial | 15 | MM | 3 |
Lung | 145 | Duodenum | 14 | Neuroendocrine | 4 |
Colon | 102 | Lymphoma | 14 | Bladder | 4 |
Hepatocellular | 96 | HNC | 6 | Malignant pleural mesothel | 2 |
Cholanglocarcinoma | 78 | Renal | 7 | Penile | 2 |
Rectal | 69 | Mucinous carcinoma | 5 | Fallopian tube carcinoma | 2 |
Glioblastoma | 68 | Prostate | 7 | Paget's Disease | 1 |
Osteosarcoma | 42 | GIST | 6 | SCPF | 1 |
Breast | 41 | ACC | 5 | Spleen | 1 |
Esophageal | 41 | Urethral | 3 | MGST | 1 |
Gallblader | 35 | Periampullary | 2 | Chordoma | 1 |
Hepatoblastoma | 36 | Melanoma | 2 |
Table: Summary of available PDX Models
Leverage our patient derived xenograft models and partner with LIDE on your next oncology research project:
- In vitro TCA compounds screening
- In vivo efficacy study
- Potential indication screening via MiniPDX assay
- Immunotherapy evaluation on huPBMC reconstituted models
Fig. Schematic of oncology R&D projects available through PDX models
Why LIDE Models:
- Many models of rare indications, drug resistant or relapsed/recurrent cancer
Because we have a MiniPDX® testing program with hospitals all over China, LIDE has been able to amass a large collection of rare 3R (resistant, relapsed, recurrent) models for testing of potential 2nd or 3rd line treatments. - Highly-specific molecular targets and hard to find genetic alterations
LIDE has validated 200+ special drug resistant and/or genetic altered PDX models, including EGFR single/double/triple mutations in lung cancer, triple negative breast cancer, and models with KRAS mutation, HER2 amplification, or ALK/ROS1/NTRK fusion, etc.
Table: LIDE resistant and genetically modified PDX modelsCancer Type Resistant to Specific Genetic Alteration NSCLC Eriotinib
Osimertinib
Crizotinib
Brigatinib
anti PD-L1 abEGFR: exon19del/T790M/L858R/exon20ins/ C797S
ALK: EML4-ALK/L1196M
cMET: ampli./exon14ski/CD47-MET
RET: KIF5B-RET
ROS1: CD74-ROS1/G2032R
KRAS: G12C
PTEN: Y68X
P13K: E726KBreast Cancer CDK4/6i TNBC/ER+ Multiple Myeloma Bortezemonib CD47+/CD38+ Cholangiocarcinoma Paclitaxel KRAS: G12C
FGFR: BICC1-FGFR2Colorectal Cancer Avastin KRAS: G12C
BRAF: V600EHematological Malignancy Rituximab
Imatinib/ Gastric Cancer Herceptin HER2: ampli
KRAS: G12CBrain Cancer / EGFR: VII
cMET: PTPRZ1-METMelanoma anti PD-1 ab BRAF: V600E Ovarian Cancer Platinum
PARPi/
- Highest testing standards
Pathological analysis will be done using H&E staining from FFPE reserved during each passage of individual PDX models by a certified pathologist under the U.S. CAP standard. WES and RNAseq will be done in most of the established models according to the highest international standards of PDX Consortium.
Download a LIDE PDX FactSheet Download a LIDE PDX and Cell Line List